Human Lung Cancer Research Articles

PLA2-MjTX-II from Bothrops moojeni snake venom exhibits antimetastatic and antiangiogenic effects on human lung cancer cells

Phospholipases A2 (PLA2s) from snake venom possess antitumor and antiangiogenic properties. In this study, we evaluated the antimetastatic and antiangiogenic effects of MjTX-II, a Lys49 PLA2 isolated from Bothrops moojeni venom, on lung cancer and endothelial cells. Using in vitro and ex vivo approaches, we demonstrated that MjTX-II reduced cell proliferation and inhibited fundamental processes for lung cancer cells (A549) growth and metastasis, such as adhesion, migration, invasion, and actin cytoskeleton decrease, without significantly interfering with non-tumorigenic lung cells (BEAS-2B). Furthermore, MjTX-II caused cell cycle alterations, increased reactive oxygen species production, modulated the expression of pro- and antiangiogenic genes, and decreased vascular endothelial growth factor (VEGF) expression in HUVECs. Finally, MjTX-II inhibited ex vivo angiogenesis processes in an aortic ring model. Therefore, we conclude that MjTX-II exhibits antimetastatic and antiangiogenic effects in vitro and ex vivo and represents a molecule that hold promise as a pharmacological model for antitumor therapy.

S100A6 could not promote the differentiation of Calu-6 lung cancer cell line.

Our previous study demonstrated that S100 calcium binding protein A6 (S100A6) impairs tumorigenesis by Calu-6 lung cancer cells, as well as inhibit their growth. However, the role that S100A6 plays in tumor cell differentiation has not been previously explored. This study aimed to confirm the effect of S100A6 on the direction of differentiation in the human lung cancer cell linem Calu-6m based on our previous published research. A S100A6-overexpressing lentiviral vector was successfully constructed in our previous study. Nude mouse tumorigenicity was then applied successfully, and 15 mice were divided into three groups (Calu-6, Calu-6/neo, Calu-6/S100A6). After 5 weeks, we detected lung cancer markers with immunohistochemistry in mice tumor tissues, including the adenocarcinoma markers, TTF-1 and NapsinA, the squamous cell carcinoma markers, P40, CK5/6 and P63, and the small cell lung cancer markers CD56, Syn, CgA, TTF-1, CK, and Ki-67. Differences among the three groups were statistically compared. All the above-mentioned markers were positive in the tumor tissues of all three groups, and there were no significant differences. S100A6 cannot promote differentiation of the undifferentiated human lung cancer cell line, Calu-6, into adenocarcinoma, squamous, or small cell carcinoma cell lines.

Antibacterial, antioxidant, and anticancer effects of green synthesized silver/silver chloride nanoparticles using Spondias pinnata bark extract

In this study, the green synthesis of silver/silver chloride nanoparticles (Ag/AgCl-NPs) using Spondias pinnata bark extract was confirmed by the color changes and a sharp absorbance peak at 415 nm determined by a UV-visible spectrometer. Scanning electron microscopy (SEM), X-ray powder diffraction (XRD), Thermal gravimetric analysis (TGA), and Fourier-transformed infrared spectroscopy (FTIR) were used to characterize the synthesized Ag/AgCl-NPs. The disc diffusion method was applied to screen the antibacterial activity of synthesized Ag/AgCl-NPs against four pathogenic bacteria such as Shigella boydii, Escherichia coli, Shigella dysenteriae, and Staphylococcus aureus. The highest antibacterial activity with the maximum zone of growth inhibition was observed against Shigella boydii. The Minimum inhibitory concentration (MIC) was recorded as 3 µg/ml for S. boydii and S. aureus, 6 µg/ml for E. coli, and 12 µg/ml for S. dysenteriae. Synthesized Ag/AgCl-NPs displayed comparatively higher scavenging activity for ABTS (IC50 = 29.87±1.36 µg/ml) than DPPH (IC50 = 27.66±4.54 µg/ml). Additionally, synthesized Ag/AgCl-NPs inhibited 76.83±0.60 % Ehrlich ascites carcinoma (EAC) cells, 78.43±1.97 % human breast cancer (MCF-7) cell lines, and 68.44±1.95 % human lung cancer (A549) cell lines growth at the concentration of 128 µg/ml. Next, synthesized Ag/AgCl-NPs showed potent toxicity against brine shrimp nauplii with an LC50 value of about 30 µg/ml.

Unveiling the anticancer potential of L-Asparaginase (ASNase) from novel Streptomyces isolate HB2AG: Purification and characterization study

L-asparaginase (ASNase) obtained from microbial origins is a significant enzyme in the commercial sphere, crucial for the treatment of acute lymphoblastic leukemia. In the current investigation, we isolated ASNase through techniques involving ammonium sulfate precipitation and DEAE sepharose anion exchange column chromatography, revealing a molecular weight of 35 kDa. The enzyme exhibited its peak activity at pH 8 and 40°C, maintaining approximately 99% of its enzymatic effectiveness. The Michaelis constant (Km) and maximum velocity (Vmax) were determined to be 0.0021 M and 714.3 µM/min, respectively. ASNase was found to be non-toxic on HEK293 cells and selectively effective against breast cancer, hepatocellular carcinoma cells, colorectal adenocarcinoma cells, Human lung cancer cell line, Neck squamous cells, and Human head carcinoma cells. Hepatocellular carcinoma cells exhibited remarkable responsiveness to ASNase, displaying an IC50 of 23 µg/mL. This led to observable changes in nuclear morphology indicative of apoptosis, as evidenced by DAPI and Annexin V-FITC staining. ASNase also showed cell migration potential on HEK293 cells. Streptomyces HB2AG ASNase’s dynamic functioning across pH and temperature ranges, as well as its stability at 40°C and cytotoxic potential, make it a promising pharmaceutical candidate for various applications.

Overexpression of transcription factor TBX5 inhibits the activation of YAP1-TEAD1 pathway to promote ferroptosis in lung cancer cells

BackgroundNon-small cell lung cancer (NSCLC) accounts for more than 80 % of lung cancer (LC) cases, making it the primary cause of cancer-related mortality worldwide. T-box transcription factor 5 (TBX5) is an important regulator of embryonic and organ development and plays a key role in cancer development. Here, our objective was to investigate the involvement of TBX5 in ferroptosis within LC cells and the underlying mechanisms. MethodsFirst, TBX5 expression was examined in human LC cells. Next, overexpression of TBX5 and Yes1-associated transcriptional regulator (YAP1) and knockdown of TEA domain 1 (TEAD1) were performed in A549 and NCI–H1703 cells. The proliferation ability of A549 and NCI–H1703 cells, GSH, MDA, ROS, and Fe2+ levels were measured. Co-immunoprecipitation (Co-IP) was performed to verify whether TBX5 protein could bind YAP1. Then TBX5, YAP1, TEAD1, GPX4, p53, FTH1, SLC7A11 and PTGS2 protein levels were assessed. Finally, we verified the effect of TBX5 on ferroptosis in LC cells in vivo. ResultsTBX5 expression was down-regulated in LC cells, especially in A549 and NCI–H1703 cells. Overexpression of TBX5 significantly decreased proliferation ability of A549 and NCI–H1703 cells, downregulated GPX4 and GSH levels, and upregulated MDA, ROS, and Fe2+ levels. Co-IP verified that TBX5 protein could bind YAP1. Moreover, oe-YAP1 promoted proliferation ability of A549 and NCI–H1703 cells transfected with Lv-TBX5, upregulated GPX4 and GSH levels and downregulated MDA, ROS, and Fe2+ levels. Additionally, oe-YAP1 promoted FTH1 and SLC7A11 levels and inhibited p53 and PTGS2 levels in A549 and NCI–H1703 cells transfected with Lv-TBX5. However, transfection with si-TEAD1 further reversed these effects. In vivo experiments further validated that TBX5 promoted ferroptosis in LC cells. ConclusionsTBX5 inhibited the activation of YAP1-TEAD1 pathway to promote ferroptosis in LC cells.

Synthesis and anticancer activity evaluation of some novel imidazo[1,2-a]pyridine based heterocycles containing S-alkyl/aryl moiety

Here we report the synthesis and anticancer activities of fourteen novel imidazo[1,2-a]pyridine derivatives (6a-6n) containing S-alkyl/aryl moiety. The target compounds were obtained via a six-step synthetic route. 1-(4-Aminophenyl)ethan-1-one was the starting material. In the last step, 2-chloro-N-[4-(imidazo[1,2-a]pyridin-2-yl)phenyl]acetamide (5) was allowed to react with various aliphatic/aromatic thiol derivatives, affording the final compounds 6a-6n. The cytotoxicity of the compounds was evaluated against A549 (human non-small cell lung cancer), C6 (rat glioma), MCF-7 (human breast carcinoma) and HepG2 (human liver carcinoma) tumor cells and NIH/3T3 (mouse embryonic fibroblast cells) healthy cells. First step MTT assay reported that compounds 6a, 6d, 6e and 6i exhibited antiproliferative activity against all tested tumor lines. Second step BrdU cell proliferation assay and flow cytometric analysis revealed that compounds 6d and 6i inhibited DNA synthesis on HepG2 cell line time-dependently by apoptotic pathway. Molecular docking study of compounds 6d and 6i with caspase-3 and caspase-9 revealed their binding interactions with the enzyme’s active site, confirming the experimental findings.

Retraction: Naringenin inhibits migration, invasion, induces apoptosis in human lung cancer cells and arrests tumour progression invitro.

Shi X, Luo X, Chen T, Guo W, Liang C, Tang S, Mo J. Naringenin inhibits migration, invasion, induces apoptosis in human lung cancer cells and arrests tumour progression invitro. J Cell Mol Med. 2021; 25: 2563-2571. https://doi.org/10.1111/jcmm.16226 The above article, published online on 1 February 2021 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Stefan N. Constantinescu, and the Foundation for Cellular and Molecular Medicine/John Wiley & Sons Ltd. Following publication, concerns were raised by third parties that portions of Figure1 are identical to Figure1 in another article (1) from a different author group and covering a different research topic. Further investigation confirmed these concerns and revealed additional duplication in Figures1 and 3, overlapping with Figures1 and 2 in (1). The authors of both articles were approached for an explanation but were unable to address the concerns raised. The authors of (1) did not respond, and the authors of this article were unable to provide any underlying data. The retraction has been agreed because of concerns regarding the integrity of the research presented given that the figures were duplicated. (1) Zhang J, Wang R, Cheng L, Xu H. Celastrol inhibit the proliferation, invasion and migration of human cervical HeLa cancer cells through down-regulation of MMP-2 and MMP-9. J Cell Mol Med. 2021; 25: 5335-5338. https://doi.org/10.1111/jcmm.16488.

Retraction: Celastrol inhibit the proliferation, invasion and migration of human cervical HeLa cancer cells through down-regulation of MMP-2 and MMP-9.

Zhang J, Wang R, Cheng L, Xu H. Celastrol inhibit the proliferation, invasion and migration of human cervical HeLa cancer cells through down-regulation of MMP-2 and MMP-9. J Cell Mol Med. 2021;25:5335-5338. doi: 10.1111/jcmm.16488 The above article, published online on 4 May 2021 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Stefan N. Constantinescu, and the Foundation for Cellular and Molecular Medicine/John Wiley & Sons Ltd. Following publication, concerns were raised by third parties that portions of Figure1 are identical to Figure1 presented in another article (1) from a different author group and covering a different research topic. Further investigation confirmed these concerns and revealed additional duplication in Figures1 and 2, overlapping with Figures1 and 3 in (1). The authors of both articles were approached for an explanation but the authors of this article did not respond. The authors of (1) were unable to provide any underlying data. The retraction has been agreed because of concerns regarding the integrity of the research presented given that the figures were duplicated. (1) Shi X, Luo X, Chen T, etal. Naringenin inhibits migration, invasion, induces apoptosis in human lung cancer cells and arrests tumour progression invitro. J Cell Mol Med. 2021;25:2563-2571. doi: 10.1111/jcmm.16226.

Synthesis of Flavonols and Assessment of Their Biological Activity as Anticancer Agents.

A series of flavanols were synthesized to assess their biological activity against human non-small cell lung cancer cells (A549). Among the sixteen synthesized compounds, it was observed that compounds 6k (3.14 ± 0.29 µM) and 6l (0.46 ± 0.02 µM) exhibited higher potency compared to 5-fluorouracil (5-Fu, 4.98 ± 0.41 µM), a clinical anticancer drug which was used as a positive control. Moreover, compound 6l (4'-bromoflavonol) markedly induced apoptosis of A549 cells through the mitochondrial- and caspase-3-dependent pathways. Consequently, compound 6l might be developed as a candidate for treating or preventing lung cancer.

Antibacterial and cytotoxicity activity of green synthesized silver nanoparticles using aqueous extract of naartjie (Citrus unshiu) fruit peels

The application of plant extracts in the green synthesis of silver nanoparticles (AgNPs) has attracted significant attention owing to their eco-friendliness and cost-effective features. However, nanoparticles synthesized from plant materials may also display unique physicochemical properties. This study described an improved synthesis process for silver nanoparticles (AgNPs) from the peel of the Citrus unshiu fruit, an agricultural waste product. In addition to evaluating the produced AgNPs' physico-chemical characteristics, the research also examines their antibacterial and cytotoxic/anticancer capabilities. The color change from yellow to dark brown was observed immediately when 20 ml of Citrus unshiu fruit peel extract was added to 0.5 g of silver nitrate. A surface plasmon resonance band at 424 nm revealed by ultra-violet spectroscopy was used as additional confirmation that AgNP had formed. The scanning electron microscope (SEM), and the transmission electron microscope (TEM), revealed spherical-shaped NPs with a mean size of 23 nm. Furthermore, X-ray diffraction (XRD) confirmed the high crystallinity of the obtained NPs while Fourier transform infrared spectroscopy (FTIR) confirmed the bioreducing capacity of the Citrus unshiu fruit peel extract. The minimum inhibitory concentration (MIC) (31.25 μg/mL) of AgNPs significantly revealed a strong dose-dependent antibacterial effect on Staphylococcus aureus and Bacillus cereus. In contrast, their impact on gram-negative bacteria, such as Escherichia coli and Salmonella typhimurium, displayed an MIC of 250 μg/mL. The assessment of cytotoxicity on human embryonic kidney cells (HEK293) and lung cancer cells (A549) through a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay revealed no detectable cytotoxic effects. The IC50 values were determined as 37.73 ± 0.34 μg/mL for HEK293 and 56.37 ± 0.73 μg/mL for A549, indicating the absence of significant adverse impacts on these cell lines. The anticancer drug doxorubicin was used as a reference standard, and had an IC50 value of 1.22 ± 0.09 and 0.76 ± 0.12 μg/mL against HEK293 and A549 cells, respectively. The results show that AgNPs synthesized from Citrus unshiu fruit peel could serve as antibacterial agents that may in the future be optimized for us in for example nanofiltration systems.

Fabrication of microfluidic pH sensing chip based on sputtered Sb2O3/Sb thin film working electrode and AgIO3/Ag thin film reference electrode for detection of A549 cells

In this study, we present the fabrication and characterization of a microfluidic pH sensing chip designed to detect human lung cancer (A549) cells. The chip utilizes a Sb2O3/Sb thin film as the working electrode and an AgIO3/Ag thin film as the reference electrode, both deposited using the radio frequency (RF) sputtering technique. The PDMS microfluidic channel was prepared using a 3D-printed mold, followed by curing of PDMS within the mold. The fabricated sensing chip demonstrated excellent linear response (R2 ∼ 0.99) and appreciable Nernstian sensitivity (average = -57.02 ± 1.23 mV/pH, n = 4) in a wide pH range of 1.68–10.01. It exhibited good stability over a 48-hour duration with acceptable drift voltage and negligible temperature impact on the sensing performance. Further, in-vitro pH testing of human lung cancer (A549) cells was performed to investigate the real-time pH measurement ability of the developed microfluidic pH sensing chip.

Cycloheptylprodigiosin from marine bacterium Spartinivicinus ruber MCCC 1K03745T induces a novel form of cell death characterized by Golgi disruption and enhanced secretion of cathepsin D in non-small cell lung cancer cell lines

Prodiginines have been studied extensively for their anticancer activity, however, the majority of the research has focused on prodigiosin. In this study, cycloheptylprodigiosin (S-1) is extracted from marine bacterium Spartinivicinus ruber MCCC 1K03745T, and its anticancer property was investigated. It exhibits remarkable cytotoxicity against a panel of human lung cancer cell lines, with the IC50 values ranging from 84.89 nM to 661.2 nM. After 6 h of treatment, S-1 gradually accumulates on mitochondria and lysosomes. While lower doses of S-1 induce cell cycle arrest, treatment with higher doses results in cell death in apoptotic independent manner in both NCI–H1299 and NCI–H460 cell lines. Interestingly, treatment with S-1 leads to the accumulation of LC3B-II via pathways that vary among different cell lines. In addition to its role as an autophagy inhibitor, S-1 also promotes autophagy initiation as demonstrated by the increment of EGFP fragment in the EGFP-LC3 degradation assay, however, inhibition of autophagy does not rescue cells from death induced by S-1. Mechanistically, S-1 impairs autophagic flux through disrupting acidic lysosomal pH and blocking the maturation of cathepsin D. Moreover, treatment with S-1 enhanced secretion of both pro- and mature forms of cathepsin D, coincident with disintegration of trans-Golgi network. Interestingly, S-1 does not induce ferroptosis, pyroptosis or necroptosis in NCI–H1299 cells. However, treatment of NCI–H460 cells with S-1 induces methuosis, which can be suppressed by Rac1 inhibitor EHT 1864. Our data demonstrate that S-1 is an effective anticancer agent with potential therapeutic application.

Alkaloids from Zanthoxylum nitidum and their anti-proliferative activity against A549 cells by regulating the EGFR/AKT/mTOR pathway

Zanthoxylum nitidum is frequently used as a traditional Chinese medicine and food supplement. Our previous study revealed that its constituent compounds were able to inhibit cancer cell proliferation. In our continuous exploration of bioactive compounds in Z. nitidum, we isolated ten alkaloids (1-10), including one new natural compound (1), and nine known alkaloids (2-10), from an ethanolic extract of the whole plant. The chemical structures were elucidated based on a combination of comprehensive NMR and HRESIMS analyses. Compounds 5, 8 and 10 exhibited significant antiproliferative effects against A549 cancer cell lines. We further elucidated the underlying molecular mechanisms of the antiproliferative activity of compound 8 in A549 human lung cancer cells. Compound 8 was found to induce cell cycle arrest in the G0/G1 phase via p53 activation and CDK4/6 suppression. Compound 8 also effectively inhibited cell migration through the modulation of the epithelial-mesenchymal transition (EMT), as indicated by the expression of biomarkers, such as N-cadherin downregulation and E-cadherin upregulation. Compound 8 significantly suppressed the activation of the EGFR/AKT/mTOR signalling pathway in A549 cells. These results indicate that alkaloid 8 from Z. nitidum has potential to be a lead antiproliferative compound in cancer cells.

Discovery of gefitinib-1,2,3-triazole derivatives against lung cancer via inducing apoptosis and inhibiting the colony formation

A series of 20 novel gefitinib derivatives incorporating the 1,2,3-triazole moiety were designed and synthesized. The synthesized compounds were evaluated for their potential anticancer activity against EGFR wild-type human non-small cell lung cancer cells (NCI-H1299, A549) and human lung adenocarcinoma cells (NCI-H1437) as non-small cell lung cancer. In comparison to gefitinib, Initial biological assessments revealed that several compounds exhibited potent anti-proliferative activity against these cancer cell lines. Notably, compounds 7a and 7j demonstrated the most pronounced effects, with an IC50 value of 3.94 ± 0.17 µmol L−1 (NCI-H1299), 3.16 ± 0.11 µmol L−1 (A549), and 1.83 ± 0.13 µmol L−1 (NCI-H1437) for 7a, and an IC50 value of 3.84 ± 0.22 µmol L−1 (NCI-H1299), 3.86 ± 0.38 µmol L−1 (A549), and 1.69 ± 0.25 µmol L−1 (NCI-H1437) for 7j. These two compounds could inhibit the colony formation and migration ability of H1299 cells, and induce apoptosis in H1299 cells. Acute toxicity experiments on mice demonstrated that compound 7a exhibited low toxicity in mice. Based on these results, it is proposed that 7a and 7j could potentially be developed as novel drugs for the treatment of lung cancer.

Bio profiling of brackish water alga Gracilaria tenuistipitata C.F.Chang & B.-M.Xia – an indigenous species from Andhra Pradesh, East Coast, India

ABSTRACT Gracilaria is one of the commercially important genera for the superior quality of phycocolloids, and high nutritional and therapeutic values. The present study is subjected to the bio-profile of the brackish water species Gracilaria tenuistipitata from the shoreline of Andhra Pradesh, East Coast, India. Proximate analysis of this species contains a high amount of carbohydrate (58.19 ± 3.52%), ash (32.64 ± 3.21%), moisture (5.84 ± 3.88%) and fiber (10.35 ± 0.595). The preliminary analysis of the algal extract confirmed the presence of alkaloids, saponins, tannins, flavonoids, steroids, glycosides, terpenoids, phenols, quinones and anthraquinones. The existence of important bioactive compounds such as ethyl oleate (18.45%), ethyl palmitate ((17%), ethyl linolenate (16.34%), phytol (12.46%) and clionasterol (8.56%) were also been confirmed in G. tenuistipitata by GCMS technique. The antibacterial potentiality of this species recorded the maximum zone of inhibition against E. coli (18.83 ± 0.6 mm), P. syringae (18 ± 1 mm) and S. aureus (17.33 ± 0.66 mm) at the concentration of 50 µg/ml. Further, this species exhibited a significant effect of antioxidant (IC50 = 24.08 ± 1.32) and anti-cancerous (IC50 = 39.90 ± 1.60 µg/ ml) activities against human lung cancer cells A459. Thus, G. tenuistipitata could be a promising element and alternative source for the potential activities.

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.

KRAS is the most frequently mutated oncogene in human cancer and facilitates uncontrolled growth through hyperactivation of the receptor tyrosine kinase (RTK)/mitogen-activated protein kinase (MAPK) pathway. The Son of Sevenless homolog 1 (SOS1) protein functions as a guanine nucleotide exchange factor (GEF) for the RAS subfamily of small GTPases and represents a druggable target in the pathway. Using a structure-based drug discovery approach, MRTX0902 was identified as a selective and potent SOS1 inhibitor that disrupts the KRAS:SOS1 protein-protein interaction to prevent SOS1-mediated nucleotide exchange on KRAS and translates into an anti-proliferative effect in cancer cell lines with genetic alterations of the KRAS-MAPK pathway. MRTX0902 augmented the antitumor activity of the KRAS G12C inhibitor adagrasib when dosed in combination in eight out of 12 KRAS G12C-mutant human non-small cell lung cancer and colorectal cancer xenograft models. Pharmacogenomic profiling in preclinical models identified cell cycle genes and the SOS2 homolog as genetic co-dependencies and implicated tumor suppressor genes (NF1 and PTEN) in resistance following combination treatment. Lastly, combined vertical inhibition of RTK/MAPK pathway signaling by MRTX0902 with inhibitors of EGFR or RAF/MEK led to greater downregulation of pathway signaling and improved antitumor responses in KRAS-MAPK pathway-mutant models. These studies demonstrate the potential clinical application of dual inhibition of SOS1 and KRAS G12C and additional SOS1 combination strategies that will aide in the understanding of SOS1 and RTK/MAPK biology in targeted cancer therapy.

CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.

Oncogenic KRAS impairs antitumor immune responses. As effective strategies to combine KRAS inhibitors and immunotherapies have so far proven elusive, a better understanding of the mechanisms by which oncogenic KRAS drives immune evasion is needed to identify approaches that could sensitize KRAS-mutant lung cancer to immunotherapy. In vivo CRISPR-Cas9 screening in an immunogenic murine lung cancer model identified mechanisms by which oncogenic KRAS promotes immune evasion, most notably via upregulation of immunosuppressive COX2 in cancer cells. Oncogenic KRAS potently induced COX2 in both mouse and human lung cancer, which was suppressed using KRAS inhibitors. COX2 acted via prostaglandin E2 (PGE2) to promote resistance to immune checkpoint blockade (ICB) in lung adenocarcinoma. Targeting COX2/PGE2 remodeled the tumor microenvironment by inducing proinflammatory polarization of myeloid cells and influx of activated cytotoxic CD8+ T cells, which increased the efficacy of ICB. Restoration of COX2 expression contributed to tumor relapse after prolonged KRAS inhibition. These results provide the rationale for testing COX2/PGE2 pathway inhibitors in combination with KRASG12C inhibition or ICB in patients with KRAS-mutant lung cancer. Significance: COX2 signaling via prostaglandin E2 is a major mediator of immune evasion driven by oncogenic KRAS that promotes immunotherapy and KRAS-targeted therapy resistance, suggesting effective combination treatments for KRAS-mutant lung cancer.

Keratin 6A (KRT6A) promotes radioresistance, invasion, and metastasis in lung cancer via p53 signaling pathway.

It is reported that the incidence rate and mortality of lung cancer are very high. Therefore, early diagnosis and identification of specific biomarkers are crucial for the clinical treatment of lung cancer. This study aims to comprehensively investigate the prognostic significance of KRT6A in human lung cancer. The GEO2R online tool was utilized to analyze the differential expression of mRNA between lung carcinoma tissues and radioresistant tissues in the GSE73095 and GSE197236 datasets. DAVID database was used to perform GO and KEGG enrichment analyses on target genes. The Kaplan-Meier plotter tool was used to analyze the impact of key messenger ribonucleic acid on the survival status of lung cancer. In addition, quantitative real-time polymerase chain reaction (qPCR) was used to investigate the impact of key genes on the phenotype of lung cancer cells. After the knockout, we conducted cell migration and CCK-8 experiments to detect their effects on cell proliferation and invasion. 40 differentially expressed genes (DEGs) were chosen from GSE73095 and 118 DEGs were chosen from GSE197236. Kaplan-Meier map analysis showed that the overall cancer survival rate of the high-expression KRT6A group was higher than that of the low-expression group (P < 0.05). Besides, cell experiments have shown that when the KRT6A gene is downregulated, the proliferation and invasion ability of lung cancer cells is weakened. Our research concluded that KRT6A may take part in the radioresistance and progression of lung cancer and can be a potential biomarker for lung cancer patients.

Alocasia macrorrhiza rhizome lectin inhibits growth of pathogenic bacteria and human lung cancer cell in vitro and Ehrlich ascites carcinoma cell in vivo in mice

Cancer and antibiotic resistance represent significant global challenges, affecting public health and healthcare systems worldwide. Lectin, a carbohydrate-binding protein, displays various biological properties, including antimicrobial and anticancer activities. This study focused on anticancer and antibacterial properties of Alocasia macrorrhiza lectin (AML). AML, with a molecular weight of 11.0 ± 1.0 kDa was purified using Ion-exchange chromatography, and the homotetrameric form was detected by gel-filtration chromatography. It agglutinates mouse erythrocytes, that was inhibited by 4-Nitrophenyl-α-d-mannopyranoside. Maximum hemagglutination activity was observed below 60 °C and within a pH range from 8 to 11. Additionally, it exhibited moderate toxicity against brine shrimp nauplii with LD50 values of 321 μg/ml and showed antibacterial activity against Escherichia coli and Shigella dysenteriae. In vitro experiments demonstrated that AML suppressed the proliferation of mice Ehrlich ascites carcinoma (EAC) cells by 35 % and human lung cancer (A549) cells by 40 % at 512 μg/ml concentration. In vivo experiments involved intraperitoneal injection of AML in EAC-bearing mice for five consecutive days at doses of 2.5 and 5.0 mg/kg/day, and the results indicated that AML inhibited EAC cell growth by 37 % and 54 %, respectively. Finally, it can be concluded that AML can be used for further anticancer and antibacterial studies.

Effects of Reduced Extracellular Sodium Concentrations on Cisplatin Treatment in Human Tumor Cells: The Role of Autophagy.

Hyponatremia is the prevalent electrolyte imbalance in cancer patients, and it is associated with a worse outcome. Notably, emerging clinical evidence suggests that hyponatremia adversely influences the response to anticancer treatments. Therefore, this study aims to investigate how reduced extracellular [Na+] affects the responsiveness of different cancer cell lines (from human colon adenocarcinoma, neuroblastoma, and small cell lung cancer) to cisplatin and the underlying potential mechanisms. Cisplatin dose-response curves revealed higher IC50 in low [Na+] than normal [Na+]. Accordingly, cisplatin treatment was less effective in counteracting the proliferation and migration of tumor cells when cultured in low [Na+], as demonstrated by colony formation and invasion assays. In addition, the expression analysis of proteins involved in autophagosome-lysosome formation and the visualization of lysosomal areas by electron microscopy revealed that one of the main mechanisms involved in chemoresistance to cisplatin is the promotion of autophagy. In conclusion, our data first demonstrate that the antitumoral effect of cisplatin is markedly reduced in low [Na+] and that autophagy is an important mechanism of drug escape. This study indicates the role of hyponatremia in cisplatin chemoresistance and reinforces the recommendation to correct this electrolyte alteration in cancer patients.